A TNFR1 antagonistic CD120a antibody such as Atrosimab has not been tested within a transplant environment; however, its ability to inhibit the inflammatory response associated with downstream TNFR1 signaling demonstrated in autoimmune diseases makes it an interesting prospect for the proposed combinatorial therapy. This evidence concerns the gene TNFRSF1A and autoimmune disease.